Johnson & Johnson Faces 67,500 Lawsuits as Judge Allows Expert Testimony
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy JNJ?
Source: Yahoo Finance
- Litigation Progress: A federal judge ruled that plaintiffs in over 67,500 lawsuits against Johnson & Johnson regarding baby powder and talc products can present expert testimony at trial, marking a significant step towards trial proceedings.
- Scientific Evidence Review: The judge aims to reevaluate scientific evidence due to changes in federal rules and the emergence of new evidence, which could significantly impact the validity of expert testimonies and the overall case outcomes.
- Historical Verdicts Overview: Johnson & Johnson has faced jury awards as high as $4.69 billion in state court cases, highlighting the legal risks and potential financial burdens associated with talc-related litigation.
- Bankruptcy Strategy Failure: Johnson & Johnson's attempts to resolve litigation through bankruptcy were rejected three times by federal courts, resulting in the suspension of most cases and illustrating the challenges the company faces in its legal battles.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 230.650
Low
190.00
Averages
218.50
High
240.00
Current: 230.650
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Reports Long-Term Efficacy of Nipocalimab in Myasthenia Gravis
- Long-Term Efficacy Data: Johnson & Johnson reports that Nipocalimab maintains disease control for over two years in generalized myasthenia gravis patients, indicating its potential as a durable treatment option that could significantly enhance patient quality of life.
- Clinical Trial Results: In the Phase 3 Vivacity-MG3 study, patients tracked for up to 120 weeks showed consistent improvements in muscle strength and daily living scores, with nearly one-third achieving sustained minimal symptom expression (MSE), highlighting the treatment's effectiveness.
- Side Effects and Safety: More than half of participants reduced corticosteroid use, with no unexpected safety concerns reported; common side effects included muscle spasms and peripheral swelling, demonstrating Nipocalimab's favorable tolerability profile.
- Future Research Directions: Nipocalimab works by blocking the neonatal Fc receptor (FcRn) to lower harmful lgG antibodies, and is being studied in other autoimmune and maternal-fetal conditions, having received multiple regulatory designations including FDA Fast Track and Breakthrough Therapy status.
See More
Johnson & Johnson Reaches Deal to Purchase Atraverse Medical
Acquisition Announcement: Johnson & Johnson has entered into an agreement to acquire a company named Atraverse Medical.
Strategic Move: This acquisition is part of Johnson & Johnson's strategy to expand its portfolio in the medical sector.
Market Impact: The deal is expected to enhance Johnson & Johnson's capabilities and offerings in the healthcare market.
Future Prospects: The acquisition may lead to new innovations and improvements in medical technologies under Johnson & Johnson's umbrella.
See More
Market Capital Flow Issues Impact Healthcare Stocks
- Healthcare Stocks Hit Hard: Despite strong quarterly results from companies like Thermo Fisher and Danaher, the lack of investor confidence in the healthcare sector has led to significant stock declines, indicating a panic among investors regarding healthcare equities.
- Capital Flow Concentration: Market funds are primarily directed towards stocks tied to data center construction, resulting in persistent selling pressure on healthcare stocks such as Abbott Labs and Cardinal Health, reflecting a risk-averse sentiment among investors towards the healthcare industry.
- IPO Market Impact: Upcoming IPOs like SpaceX are likely to attract substantial capital, further weakening healthcare stock performance, reminiscent of the capital concentration seen during the internet bubble in 1999, which could lead to further declines in healthcare stock P/E ratios.
- Key Earnings Reports from Tech Giants: The upcoming earnings reports from Alphabet, Amazon, Meta, and Microsoft will be crucial; if two of these companies perform well, it may boost market sentiment, whereas poor results could exacerbate downward pressure on healthcare stocks.
See More
Johnson & Johnson Launches Drugs on TrumpRx
- Expanded Drug Sales: Johnson & Johnson will sell its blood thinner Xarelto and type 2 diabetes medication Invokana through the TrumpRx website, aiming to enhance drug accessibility and meet market demand, which is expected to increase the company's market share in diabetes and cardiovascular sectors.
- Discount Agreement: The company has agreed to provide some drugs at discounted prices and build new plants in exchange for tariff exemptions on imported drugs, a move that not only helps reduce patient costs but may also strengthen the company's collaboration with the government.
- Manufacturing Investment: Johnson & Johnson plans to invest $1 billion to build a cell therapy manufacturing facility in Pennsylvania, which is expected to enhance its production capacity in the biopharmaceutical sector and lay the groundwork for future product innovations, further driving company growth.
- Market Performance Analysis: Despite facing six consecutive days of losses, the new drug sales channels and manufacturing investments may lead to a rebound in the future, boosting investor confidence and improving stock performance.
See More
Johnson & Johnson to Market Drugs on TrumpRx Website
- Drug Marketing Agreement: Johnson & Johnson has reached an agreement with the Trump administration to market four medications on the TrumpRx website, aiming to enhance affordability for Americans and strengthen its competitive position in the pharmaceutical market.
- Price Reduction Commitment: The agreement, established in January, involves J&J pledging to lower drug prices to expand prescription access under Medicaid, thereby meeting the needs of more patients and enhancing the company's brand image.
- Tariff Exemption Exchange: In exchange for this agreement, J&J received a tariff exemption from the Trump administration, which will help reduce its production costs and further enhance its price competitiveness in the market.
- Market Reaction Pending: Although J&J has not disclosed the specific four drugs, this initiative may impact its stock price and market share, prompting investors to monitor subsequent market feedback and sales data.
See More
JOHNSON & JOHNSON TO INTRODUCE 4 PRESCRIPTION DRUGS ON TRUMPRX - CBS NEWS
Johnson & Johnson Launches New Drug: Johnson & Johnson has introduced a new prescription drug aimed at treating specific medical conditions, marking a significant development in their pharmaceutical offerings.
Focus on Prescription Drugs: The launch emphasizes the company's commitment to advancing healthcare solutions through innovative prescription medications.
See More
Johnson & Johnson Reports Long-Term Efficacy of Nipocalimab in Myasthenia Gravis
- Long-Term Efficacy Data: Johnson & Johnson reports that Nipocalimab maintains disease control for over two years in generalized myasthenia gravis patients, indicating its potential as a durable treatment option that could significantly enhance patient quality of life.
- Clinical Trial Results: In the Phase 3 Vivacity-MG3 study, patients tracked for up to 120 weeks showed consistent improvements in muscle strength and daily living scores, with nearly one-third achieving sustained minimal symptom expression (MSE), highlighting the treatment's effectiveness.
- Side Effects and Safety: More than half of participants reduced corticosteroid use, with no unexpected safety concerns reported; common side effects included muscle spasms and peripheral swelling, demonstrating Nipocalimab's favorable tolerability profile.
- Future Research Directions: Nipocalimab works by blocking the neonatal Fc receptor (FcRn) to lower harmful lgG antibodies, and is being studied in other autoimmune and maternal-fetal conditions, having received multiple regulatory designations including FDA Fast Track and Breakthrough Therapy status.
See More
Johnson & Johnson Reaches Deal to Purchase Atraverse Medical
Acquisition Announcement: Johnson & Johnson has entered into an agreement to acquire a company named Atraverse Medical.
Strategic Move: This acquisition is part of Johnson & Johnson's strategy to expand its portfolio in the medical sector.
Market Impact: The deal is expected to enhance Johnson & Johnson's capabilities and offerings in the healthcare market.
Future Prospects: The acquisition may lead to new innovations and improvements in medical technologies under Johnson & Johnson's umbrella.
See More
Market Capital Flow Issues Impact Healthcare Stocks
- Healthcare Stocks Hit Hard: Despite strong quarterly results from companies like Thermo Fisher and Danaher, the lack of investor confidence in the healthcare sector has led to significant stock declines, indicating a panic among investors regarding healthcare equities.
- Capital Flow Concentration: Market funds are primarily directed towards stocks tied to data center construction, resulting in persistent selling pressure on healthcare stocks such as Abbott Labs and Cardinal Health, reflecting a risk-averse sentiment among investors towards the healthcare industry.
- IPO Market Impact: Upcoming IPOs like SpaceX are likely to attract substantial capital, further weakening healthcare stock performance, reminiscent of the capital concentration seen during the internet bubble in 1999, which could lead to further declines in healthcare stock P/E ratios.
- Key Earnings Reports from Tech Giants: The upcoming earnings reports from Alphabet, Amazon, Meta, and Microsoft will be crucial; if two of these companies perform well, it may boost market sentiment, whereas poor results could exacerbate downward pressure on healthcare stocks.
See More
Johnson & Johnson Launches Drugs on TrumpRx
- Expanded Drug Sales: Johnson & Johnson will sell its blood thinner Xarelto and type 2 diabetes medication Invokana through the TrumpRx website, aiming to enhance drug accessibility and meet market demand, which is expected to increase the company's market share in diabetes and cardiovascular sectors.
- Discount Agreement: The company has agreed to provide some drugs at discounted prices and build new plants in exchange for tariff exemptions on imported drugs, a move that not only helps reduce patient costs but may also strengthen the company's collaboration with the government.
- Manufacturing Investment: Johnson & Johnson plans to invest $1 billion to build a cell therapy manufacturing facility in Pennsylvania, which is expected to enhance its production capacity in the biopharmaceutical sector and lay the groundwork for future product innovations, further driving company growth.
- Market Performance Analysis: Despite facing six consecutive days of losses, the new drug sales channels and manufacturing investments may lead to a rebound in the future, boosting investor confidence and improving stock performance.
See More
Johnson & Johnson to Market Drugs on TrumpRx Website
- Drug Marketing Agreement: Johnson & Johnson has reached an agreement with the Trump administration to market four medications on the TrumpRx website, aiming to enhance affordability for Americans and strengthen its competitive position in the pharmaceutical market.
- Price Reduction Commitment: The agreement, established in January, involves J&J pledging to lower drug prices to expand prescription access under Medicaid, thereby meeting the needs of more patients and enhancing the company's brand image.
- Tariff Exemption Exchange: In exchange for this agreement, J&J received a tariff exemption from the Trump administration, which will help reduce its production costs and further enhance its price competitiveness in the market.
- Market Reaction Pending: Although J&J has not disclosed the specific four drugs, this initiative may impact its stock price and market share, prompting investors to monitor subsequent market feedback and sales data.
See More
JOHNSON & JOHNSON TO INTRODUCE 4 PRESCRIPTION DRUGS ON TRUMPRX - CBS NEWS
Johnson & Johnson Launches New Drug: Johnson & Johnson has introduced a new prescription drug aimed at treating specific medical conditions, marking a significant development in their pharmaceutical offerings.
Focus on Prescription Drugs: The launch emphasizes the company's commitment to advancing healthcare solutions through innovative prescription medications.
See More
